Advertisement

Advertisement

DE:015A Stock Latest News

Rein Therapeutics Highlights LTI-03 Progress in IPF

Company AnnouncementsRein Therapeutics Highlights LTI-03 Progress in IPF

Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price

PremiumCompany Announcements

Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price

1M ago

Rein Therapeutics granted Fast Track designation for LTI-03

PremiumThe Fly

Rein Therapeutics granted Fast Track designation for LTI-03

2M ago

Analyst Reaffirms Buy on Rein Therapeutics With Unchanged $4 Target as Phase 2 IPF Trial Advances and Cash Runway Extends to 2028

PremiumRatings

Analyst Reaffirms Buy on Rein Therapeutics With Unchanged $4 Target as Phase 2 IPF Trial Advances and Cash Runway Extends to 2028

2M ago

Buy Rating Reaffirmed on LTI-03 Data and Upcoming RENEW Trial, Price Target Maintained at $8

PremiumRatings

Buy Rating Reaffirmed on LTI-03 Data and Upcoming RENEW Trial, Price Target Maintained at $8

2M ago

Rein Therapeutics Shareholders Approve Governance and Stock Changes

PremiumCompany AnnouncementsRein Therapeutics Shareholders Approve Governance and Stock Changes

3M ago

Rein Therapeutics announces RENEW clinical trial open for enrollment

The Fly

Rein Therapeutics announces RENEW clinical trial open for enrollment

3M ago

Maxim starts Rein Therapeutics at Buy amid de-risked LTI-03 program

The Fly

Maxim starts Rein Therapeutics at Buy amid de-risked LTI-03 program

3M ago

Rein Therapeutics initiated with a Buy at Maxim

PremiumThe Fly

Rein Therapeutics initiated with a Buy at Maxim

3M ago

Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright

PremiumThe Fly

Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright

4M ago

Rein Therapeutics Prices $50 Million Public Equity Offering

PremiumCompany Announcements

Rein Therapeutics Prices $50 Million Public Equity Offering

5M ago

Rein Therapeutics provides update on RENEW clinical trial

PremiumThe Fly

Rein Therapeutics provides update on RENEW clinical trial

5M ago

Rein Therapeutics files to sell 30M shares of common stock

PremiumThe FlyRein Therapeutics files to sell 30M shares of common stock

5M ago

RNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pre-Earnings

RNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

6M ago

Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

The Fly

Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

6M ago

Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside

PremiumRatings

Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside

6M ago

Rein Therapeutics doses first patient in Phase 2 trial of LTI-03

PremiumThe Fly

Rein Therapeutics doses first patient in Phase 2 trial of LTI-03

7M ago

Rein Therapeutics Completes Private Placement of Notes

PremiumCompany Announcements

Rein Therapeutics Completes Private Placement of Notes

7M ago

Rein Therapeutics Announces Immediate Board Director Resignation

PremiumCompany Announcements

Rein Therapeutics Announces Immediate Board Director Resignation

8M ago

Rein Therapeutics downgraded to Hold from Buy at Brookline

PremiumThe FlyRein Therapeutics downgraded to Hold from Buy at Brookline

9M ago

Rein Therapeutics receives orphan drug designation from EMA for LTI-03

The Fly

Rein Therapeutics receives orphan drug designation from EMA for LTI-03

9M ago

Rein Therapeutics Raises Capital via Private Note Offering

Company Announcements

Rein Therapeutics Raises Capital via Private Note Offering

9M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >